AC Immune SA

NasdaqGM:ACIU Stock Report

Market Cap: US$374.9m

AC Immune Management

Management criteria checks 3/4

AC Immune's CEO is Andrea Pfeifer, appointed in Apr 2003, has a tenure of 21.25 years. total yearly compensation is CHF2.65M, comprised of 21.8% salary and 78.2% bonuses, including company stock and options. directly owns 2.58% of the company’s shares, worth $9.66M. The average tenure of the management team and the board of directors is 3.8 years and 6.3 years respectively.

Key information

Andrea Pfeifer

Chief executive officer

CHF 2.7m

Total compensation

CEO salary percentage21.8%
CEO tenure21.3yrs
CEO ownership2.6%
Management average tenure3.8yrs
Board average tenure6.3yrs

Recent management updates

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Recent updates

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

CEO Compensation Analysis

How has Andrea Pfeifer's remuneration changed compared to AC Immune's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-CHF 55m

Dec 31 2023CHF 3mCHF 578k

-CHF 54m

Sep 30 2023n/an/a

-CHF 68m

Jun 30 2023n/an/a

-CHF 67m

Mar 31 2023n/an/a

-CHF 69m

Dec 31 2022CHF 2mCHF 558k

-CHF 71m

Sep 30 2022n/an/a

-CHF 73m

Jun 30 2022n/an/a

-CHF 76m

Mar 31 2022n/an/a

-CHF 75m

Dec 31 2021CHF 2mCHF 530k

-CHF 73m

Sep 30 2021n/an/a

-CHF 71m

Jun 30 2021n/an/a

-CHF 74m

Mar 31 2021n/an/a

-CHF 71m

Dec 31 2020CHF 2mCHF 520k

-CHF 62m

Sep 30 2020n/an/a

-CHF 62m

Jun 30 2020n/an/a

-CHF 25m

Mar 31 2020n/an/a

-CHF 26m

Dec 31 2019CHF 2mCHF 510k

CHF 45m

Sep 30 2019n/an/a

CHF 50m

Jun 30 2019n/an/a

CHF 18m

Mar 31 2019n/an/a

CHF 24m

Dec 31 2018CHF 2mCHF 455k

-CHF 51m

Sep 30 2018n/an/a

-CHF 32m

Jun 30 2018n/an/a

-CHF 27m

Mar 31 2018n/an/a

-CHF 29m

Dec 31 2017CHF 2mCHF 404k

-CHF 26m

Compensation vs Market: Andrea's total compensation ($USD2.95M) is about average for companies of similar size in the US market ($USD2.43M).

Compensation vs Earnings: Andrea's compensation has increased whilst the company is unprofitable.

CEO

Andrea Pfeifer (67 yo)

21.3yrs

Tenure

CHF 2,650,000

Compensation

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Leadership Team

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder21.3yrsCHF 2.65m2.58%
CHF 9.7m
Christopher Roberts
CFO & VP of Finance2.3yrsno data0.013%
CHF 50.3k
Piergiorgio Donati
Chief Technical Operations Officer5.4yrsno data0.026%
CHF 97.8k
Jean-Fabien Monin
Chief Administrative Officer9yrsno data0.33%
CHF 1.2m
Howard Donovan
Chief HR Officer2.3yrsno data0.021%
CHF 80.3k
Nuno Mendonca
Chief Medical Officerless than a yearno data0.0088%
CHF 32.8k
Madiha Derouazi
Chief Scientific Officerless than a yearno data0.0034%
CHF 12.7k
Gary Waanders
Senior VP of Investor Relations & Corporate Communicationsno datano datano data
Alexandre Caratsch
General Counselno datano datano data
Julian Snow
VP of U.S. Finance & Corporate Development2.3yrsno datano data
David Hickman
Head of AD - SME14.5yrsno datano data
Joseph Wettstein
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer8.4yrsno datano data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Management: ACIU's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder8.2yrsCHF 2.65m2.58%
CHF 9.7m
Jean-Marie Lehn
Chairman of Scientific Advisory Boardno datano datano data
Claude Nicolau
Member of Scientific Advisory Boardno datano datano data
Douglas Williams
Independent Non-Executive Chairman6.3yrsCHF 179.00k0.041%
CHF 155.3k
Alf E. Lindberg
Member of Scientific Advisory Boardno datano datano data
Detlev Riesner
Member of Scientific Advisory Boardno dataCHF 5.00kno data
Fred Van Leuven
Member of Scientific Advisory Boardno dataCHF 105.00kno data
I. Rosenberg
Member of Scientific Advisory Boardno datano datano data
M. Monsigny
Member of Scientific Advisory Boardno datano datano data
E. Lestringant
Member of Scientific Advisory Boardno datano datano data
Monika Butler
Independent Vice Chair2.8yrsCHF 163.00k0.0097%
CHF 36.5k
Andreas Monsch
Head of Clinical Advisory Boardno datano datano data

6.3yrs

Average Tenure

74.5yo

Average Age

Experienced Board: ACIU's board of directors are considered experienced (6.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.